

LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

EXAMPLE, REPORT W

WX0000003827 M 07/08/1978 45 Y

Referral Testing							
		Collected:	09/07/2023	09:01	Received:	09/07/2023	09:01
<u>Test Name</u>	Result		Flag	Ref-Ranges	<u> </u>	<u>Units</u>	<u>Site</u>
S. pneumoniae IgG ABS 14 Stypes							
Serotype 1 (1)	3.4						QCRL
Serotype 3 (3)	< 0.3						QCRL
Serotype 4 (4)	0.6						QCRL
Serotype 5 (5)	0.9						QCRL
Serotype 8 (8)	< 0.3						QCRL
Serotype 9 (9N)	<0.3						QCRL
Serotype 12 (12F)	<0.3						QCRL
Serotype 14 (14)	11.1						QCRL
Serotype 19 (19F)	8.0						QCRL
Serotype 23 (23F)	<0.3						QCRL
Serotype 26 (6B)	1.3						QCRL
Serotype 51 (7F)	4.9						QCRL
Serotype 56 (18C)	0.6						QCRL
Serotype 68 (9V)	0.3						QCRL

Serologic correlates of protection against pneumococcal disease have not been rigorously established for all patient populations. Published data and expert consensus (including WHO) suggest protection from invasive disease usually occurs at levels >or =0.3-0.50 mcg/mL for healthy children receiving pneumococcal conjugate vaccines. Higher titers may be necessary to protect from non-invasive infection (e.g., pneumonia, otitis, sinusitis). Expert opinion suggests that a cut-off of \geq 1.3 mcg/mL may be a more relevant value to assess antibody responses after pneumococcal polysaccharide vaccines or for immunocompromised patients. In addition to antibody quantity, protection also depends on antibody avidity and opsonophagocytic activity. Some experts consider that post-vaccination (4-6 weeks) IgG seroconversion and/or 2- to 4-fold rise in IgG titers for >50% to 70% of vaccine serotypes demonstrates a normal post-vaccine serologic response. Persons with high initial serotype-specific titers may have less robust responses.

Quest Diagnostics uses a multi-analyte immunodetection (MAID) method. The method employs the Luminex flow cytometric system which measures multiple analytes simultaneously. The FDA standard reference serum 89-S is used as the calibration standard. Results are reported in mcg/mL.

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, $\,$. - NOT TESTED

F307000006 WX0000003827 Printed D&T: 09/07/23 09:03 Ordered By: KAJAL SITWALA, MD, PhD WX00000000002365



LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 **EXAMPLE, REPORT W**

WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 09/07/2023 09:01 Received: 09/07/2023 09:01

<u>Test Name</u> <u>Result</u> <u>Flag Ref-Ranges</u> <u>Units</u> <u>Site</u>

This assay detects 11 of the 13 serotypes in the 13-valent conjugate vaccine, and 14 of the 23 serotypes in the 23-valent polysaccharide vaccine.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

For additional information, please refer to (This link is being provided for informational/educational purposes only.)

Test Performed at: Quest Diagnostics Nichols Institute 33608 Ortega Highway San Juan Capistrano, CA 92675-2042

I Maramica MD, PhD

Performing Site:

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

Reported Date: 2023.09.07 9:03 PNE14

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, $\,$. - NOT TESTED

F307000006 WX0000003827 Printed D&T: 09/07/23 09:03 Ordered By: KAJAL SITWALA, MD, PhD WX00000000002365

Kajal V. Sitwala, MD, PhD - Medical Director Form: MM RL1 PAGE 2 OF 2